Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Auteurs : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S
Jaar : 2023
Journal : Eur J Cancer
Volume : 181
Pagina's : 92-101

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.

Auteurs : Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I
Jaar : 2023
Journal : J Natl Compr Canc Netw
Volume : 21
Pagina's : 33-41.e16

Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer.

Auteurs : Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Jaar : 2023
Journal : Oncol Res Treat

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Auteurs : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Jaar : 2023
Journal : ESMO Open
Volume : 8
Pagina's : 100772

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.

Auteurs : Poggio F, Tagliamento M, Ceppi M, Bruzzone M, Conte B, Fregatti P, Punie K, de Azambuja E, Del Mastro L, Lambertini M
Jaar : 2022
Journal : Ann Oncol
Volume : 33
Pagina's : 347-349

Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.

Auteurs : Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E
Jaar : 2022
Journal : Breast Cancer Res Treat
Volume : 192
Pagina's : 457-462

Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel.

Auteurs : Martel S, Lambertini M, de Azambuja E
Jaar : 2022
Journal : J Natl Compr Canc Netw
Volume : 20
Pagina's : xlv-xlvi

How we treat patients with metastatic HER2-positive breast cancer.

Auteurs : Nader-Marta G, Martins-Branco D, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100343

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.

Auteurs : Bachir B, Anouti S, Abi Jaoude J, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan YH
Jaar : 2022
Journal : Int J Radiat Oncol Biol Phys
Volume : 113
Pagina's : 135-142

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.

Auteurs : Caparica R, Ma Y, de Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E
Jaar : 2022
Journal : Clin Breast Cancer
Volume : 22
Pagina's : 308-318

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).

Auteurs : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Jaar : 2022
Journal : Breast Cancer Res Treat
Volume : 191
Pagina's : 225

De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence.

Auteurs : Conte B, Soldato D, Razeti MG, Fregatti P, de Azambuja E, Schettini F, Prat A, Del Mastro L, Lambertini M
Jaar : 2022
Journal : Clin Breast Cancer
Volume : 22
Pagina's : 78-87

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Auteurs : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Jaar : 2022
Journal : Eur J Cancer
Volume : 168
Pagina's : 138-140

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Auteurs : Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E
Jaar : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pagina's : 1117-1126

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY

Auteurs : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M
Jaar : 2022
Journal : Eur J Cancer
Volume : 166
Pagina's : 219-228

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

Auteurs : Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M
Jaar : 2022
Journal : Expert Opin Investig Drugs
Volume : 31
Pagina's : 567-591

HER2-Low Breast Cancer: Where Are We?

Auteurs : Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, de Azambuja E, Schettini F, Agostinetto E, Lambertini M
Jaar : 2022
Journal : Breast Care (Basel)
Volume : 17
Pagina's : 533-545

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

Auteurs : Geukens T, Brandão M, Laenen A, Collignon J, Van Marcke C, Louviaux I, Demey W, Van Wambeke S, Schrijvers D, Lecomte S, Mebis J, Rutten A, Fontaine C, Lybaert W, Aspeslagh S, Goeminne JC, Van den Bulck H, Seront E, De Backer L, De Roock W, Ignatiadis M, Prenen H, Van Beckhoven D, Heijlen M, Verheezen J, Rottey S, Punie K, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100610

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Auteurs : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Jaar : 2022
Journal : Cancers (Basel)
Volume : 14

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Auteurs : Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C
Jaar : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pagina's : 1720-1727